Piclamilast
![[3H]-Piclamilast and [3H]-Rolipram](http://data.docslib.org/img/264x/01df065d2d9173fcecd94f732f9ed096.webp)
Top View
- Customs Tariff - Schedule
- Pathobiological Mechanisms and Treatment of Electrophysiological Dysfunction Following Primary Blast-Induced Traumatic Brain Injury
- Elevated Intracellular Camp Concentration Mediates Growth Suppression in Glioma Cells
- Anti‑Inflammatory Effect of Ciclamilast in an Allergic Model Involving the Expression of PDE4B
- 2010-Poster Tms
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- PR 6 2010.Vp:Corelventura
- (12) Patent Application Publication (10) Pub. No.: US 2013/0252924 A1 Penninger Et Al
- WO 2018/005695 Al O
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- FMO3 Inhibitors for Treating Pain
- Phosphodiesterase 4 Inhibition Reduces Lung Fibrosis Following Targeted Type II Alveolar Epithelial Cell Injury
- WO 2018/055211 Al 29 March 2018 (29.03.2018) W !P O PCT
- Pharmaabkommen A1 E
- Roles of Roflumilast, a Selective Phosphodiesterase 4 Inhibitor, in Airway Diseases
- Customs Tariff - Schedule Xxi - 1
- Literature Search Strategy for Treatment of Stable
- (12) Patent Application Publication (10) Pub. No.: US 2003/0144300 A1 Magee Et Al